共 50 条
- [1] A phase II study of the combination of BKM120 (buparlisib) and bevacizumab in patients with relapsed/refractory glioblastoma multiforme (GBM).JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)Shih, Kent C.Chowdhary, Sajeel A.Becker, Kevin P.Baehring, Joachim M.Liggett, William H.Burris, Howard A.Hainsworth, John D.
- [2] A phase II study of buparlisib in relapsed or refractory thymomasFRONTIERS IN ONCOLOGY, 2022, 12Abu Zaid, Mohammad I.Radovich, MilanAlthouse, SandraLiu, HaoSpittler, Aaron J.Solzak, JeffreyBadve, SunilLoehrer Sr, Patrick J.
- [3] A Phase I Study of BKM120 (Buparlisib) and Rituximab in Patients with Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma (NHL)BLOOD, 2015, 126 (23)Maddocks, Kami J.Cohen, Jonathon B.Christian, Beth A.Benson, Don M.Blum, Kristie A.
- [4] An Open-Label Phase II Study of Buparlisib (BKM120) in Patients with Relapsed and Refractory Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma or Follicular LymphomaBLOOD, 2014, 124 (21)Younes, AnasSalles, GillesBociek, R. GregoryMartinelli, GiovanniCaballero, DoloresGonzalez Barca, EvaMukherjee, NabanitaWilliams, LisaHerbst, FabianTavorath, RanjanaKim, Won Seog
- [5] Preclinical and clinical evaluation of Buparlisib (BKM120) in recurrent/refractory Central Nervous System LymphomaLEUKEMIA & LYMPHOMA, 2023, : 1545 - 1553Grommes, ChristianPentsova, ElenaSchaff, Lauren R. R.Nolan, Craig P. P.Kaley, ThomasReiner, Anne S. S.Panageas, Katherine S. S.Mellinghoff, Ingo K. K.
- [6] a Phase I Study of BKM120 (Buparlisib) and Rituximab in Patients with Relapsed or Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (NHL)BLOOD, 2016, 128 (22)Maddocks, Kami J.Cohen, Jonathon B.Huang, YingChristian, Beth A.Benson, Don M.Jones, JeffreyFlowers, ChristopherHeffner, Leonard T.Jenkins, CynthiaSexton, JennferNeal, AlisonKives, MelissaBlum, Kristie A.
- [7] Phase II trial of the phosphatidyinositol-3 kinase (PLIK) inhibitor buparlisib (BKM120) in recurrent glioblastomaJOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)Wen, Patrick Y.Yung, W. K. AlfredMellinghoff, Ingo K.Ramkissoon, ShaktiAlexander, Brian MichaelRinne, Mikael L.Colman, HowardOmura, Antonio MarcIllo PaduiaDeAngelis, Lisa MarieGilbert, Mark R.De Groot, John FrederickCloughesy, Timothy FrancisChi, Andrew S.Lee, Eudocia QuantNayak, LakshmiBatchelor, TracyChang, Susan MarinaPrados, MichaelReardon, David A.Ligon, Keith L.
- [8] Phase I/II study of bevacizumab with BKM120, an oral PI3K inhibitor, in patients with refractory solid tumors (phase I) and relapsed/refractory glioblastoma (phase II)JOURNAL OF NEURO-ONCOLOGY, 2019, 144 (02) : 303 - 311Hainsworth, John D.Becker, Kevin P.Mekhail, TarekChowdhary, Sajeel A.Eakle, Janice FaulknerWright, DavidLangdon, Robert M.Yost, Kathleen J.Padula, Gilbert Darin AnthonyWest-Osterfield, KimberlyScarberry, MeredithShaifer, Candice A.Shastry, MythiliBurris, Howard A., IIIShih, Kent
- [9] Phase I/II study of bevacizumab with BKM120, an oral PI3K inhibitor, in patients with refractory solid tumors (phase I) and relapsed/refractory glioblastoma (phase II)Journal of Neuro-Oncology, 2019, 144 : 303 - 311John D. HainsworthKevin P. BeckerTarek MekhailSajeel A. ChowdharyJanice Faulkner EakleDavid WrightRobert M. LangdonKathleen J. YostGilbert Darin Anthony PadulaKimberly West-OsterfieldMeredith ScarberryCandice A. ShaiferMythili ShastryHoward A. BurrisKent Shih
- [10] Buparlisib (BKM120) in refractory head and neck squamous cell carcinoma harbouring or not a PI3KCA mutation: A phase II multicenter trialANNALS OF ONCOLOGY, 2019, 30 : 455 - 455Fayette, J.Digue, L.Segura-Ferlay, C.Treilleux, I.Wang, Q.Lefebvre, G.Daste, A.Even, C.Thaunat, S. CouchonGuyennon, A.Peyrade, F.Cupissol, D.You, B.Le Tourneau, C.Jaouen, L.Grinand, E.Tabone-Eglinger, S.Garin, G.Perol, D.